𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P450 17α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors

✍ Scribed by Jarman, Michael; Barrie, S. Elaine; Llera, Jose M.

Book ID
120250789
Publisher
American Chemical Society
Year
1998
Tongue
English
Weight
141 KB
Volume
41
Category
Article
ISSN
0022-2623

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ChemInform Abstract: The 16,17-Double Bo
ChemInform Abstract: The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P45017α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors.
✍ Michael Jarman; S. Elaine Barrie; Jose M. Llera 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 40 KB 👁 1 views

The 16,17-Double Bond Is Needed for Irreversible Inhibition of Human Cytochrome P450 17α by Abiraterone (17-(3-Pyridyl)androsta-5,16-dien-3β-ol) and Related Steroidal Inhibitors. -Investigation of the structural features required for irreversible binding of steroidal inhibitors, e.g. (I)-(VI), to th

Active-site conformation of 17-(3-pyridy
Active-site conformation of 17-(3-pyridyl)androsta-5,16-dien-3β-ol, a potent inhibitor of the P450 enzyme C17α-hydroxylase/C17-20 lyase
✍ David F. Burke; Charles A. Laughton; Chris F. Snook; Stephen Neidle; Gerard A. P 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 228 KB

17-(3-pyridyl)androsta-5,16-dien-3[~-ol, a nanomolar inhibitor of the P450 enzyme C17ct-hydroxylase/C17-20 lyase, is a target for prostate cancer chemotherapy. A model is presented for the inhibitor docked into the structure of the enzyme.